Vadim V. Kozlov

Timakova Street, 2/12, 
Novosibirsk, NVS, RU 
Timakova Street, 2/12, 
Novosibirsk, NVS, RU 

Overview

Vadim Kozlov practices practicing medicine in Novosibirsk, Russian Federation.

His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Lung Carcinoma, and Renal Cell Carcinoma (RCC).

He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Timakova Street, 2/12, Novosibirsk, NVS 630117, Russian Federation

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

20 Total Publications

A Multi-Level miRNA Regulatory Network Associated with IRF1 Expression in Non-Small Cell Lung Cancer: In Silico Identification of Candidate Biomarkers for Immunotherapy Response.
A Multi-Level miRNA Regulatory Network Associated with IRF1 Expression in Non-Small Cell Lung Cancer: In Silico Identification of Candidate Biomarkers for Immunotherapy Response.
Journal: International journal of molecular sciences
Published: April 13, 2026

Frequently Asked Questions about Vadim V. Kozlov

Is Vadim V. Kozlov a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Vadim V. Kozlov is classified as an Experienced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Vadim V. Kozlov participate in research or clinical trials?

Yes. Vadim V. Kozlov has published 20 articles and abstracts on conditions like Lung Cancer. You can view a list of Vadim V. Kozlov's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kozlov's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile